Corticosteroid use in COVID-19 pneumonia

Basit Öğe Kaydı
dc.authoridyildiz gulhan, pinar/0000-0002-5347-2365
dc.authoridSogut Akdag, Devrim/0000-0002-0977-9140
dc.authoridBerik Safci, Sinem/0000-0002-0977-0015
dc.authoridDeniz, Pelin Pinar/0000-0002-9047-7608
dc.authoridOzkaya, Sevket/0000-0002-8697-4919
dc.authorwosidyildiz gulhan, pinar/AAW-3004-2020
dc.contributor.authorDiken, Ozlem Ercen
dc.contributor.authorYildirim, Fatma
dc.contributor.authorGulhan, Pinar Yildiz
dc.contributor.authorOzkaya, Sevket
dc.contributor.authorSimsek, Meltem
dc.contributor.authorYucel, Cihan
dc.contributor.authorDirican, Adem
dc.date.accessioned2021-12-01T18:51:01Z
dc.date.available2021-12-01T18:51:01Z
dc.date.issued2021
dc.department[Belirlenecek]en_US
dc.description.abstractIntroduction: Coronavirus disease 2019 (COVID-19) has a 1-2% fatality rate, where no specific treatment has yet been defined. Although corticosteroids are recommended for selected COVID-19 patients without acute respiratory distress syndrome (ARDS) and septic shock, there is no consensus regarding patient subgroups, dose, and duration. In this study, it was aimed to examine the contribution of corticosteroid treatment to the management of COVID-19 pneumonia without ARDS, septic shock both in acute and recovery setting. Materials and Methods: The study population was divided into two as those who used corticosteroids during the recovery phase (who did not develop sufficient radiological or clinical improvement) and those who did so during the activation phase (non-ARDS/septic shock condition, clinical, laboratory or radiological progression). Results: We identified 47 patients, 26 of which were males, and mean age was 60.5 +/- 16.5 years. Seventeen patients were found to receive corticosteroids during the recovery phase and the rest (n- 30) during the activation period. After corticosteroid therapy, we found reduction of increased pre-treatment levels of D-dimer, ferritin, fibrinogen, CRI; increment of decreased pre-treatment lymphocyte count and saturation. Complete symptomatic improvement was detected in 6.9% and 17.6% of the patients in the activation phase and recovery phase, respectively. Complete radiological improvement was found in 11.5% and 35.3% of the patients in the activation phase and recovery phase, respectively. While corticosteroid treatment was initiated on day 4.2 +/- 2.6 and continued for a mean of 5.9 +/- 2.8 days in the activation group, it was started on day 8.1 +/- 11.3 and administered for 7.8 +/- 3.8 days in the recovery group. In both groups, methylprednisolone was given at a median dose of 40 mg/day. Conclusion: Short-term low-dose corticosteroid therapy may improve clinical, radiological, laboratory outcomes in the management of COVID-19 pneumonia during the activation period without ARDS and non-septic shock and during recovery period with no satisfactory response. Further randomized controlled studies will be useful in demonstrating its efficacy.en_US
dc.identifier.doi10.5578/tt.20219811
dc.identifier.endpage226en_US
dc.identifier.issn0494-1373
dc.identifier.issue2en_US
dc.identifier.pmid34256512en_US
dc.identifier.scopus2-s2.0-85111461163en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage217en_US
dc.identifier.urihttps://doi.org/10.5578/tt.20219811
dc.identifier.urihttps://hdl.handle.net/20.500.12684/10956
dc.identifier.volume69en_US
dc.identifier.wosWOS:000670437700010en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherTurkish Assoc Tuberculosis & Thoraxen_US
dc.relation.ispartofTuberkuloz Ve Toraks-Tuberculosis And Thoraxen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCOVID-19en_US
dc.subjectmethylprednisoloneen_US
dc.subjectcorticosteroiden_US
dc.subjectDiseaseen_US
dc.titleCorticosteroid use in COVID-19 pneumoniaen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
10956.pdf
Boyut:
5.86 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu